JCV-specific cell-based assays for PML risk assessment in lupus and multiple sclerosis patients with and without natalizumab.

ABSTRACT:

Background

Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection caused by the JC virus and often fatal. Natalizumab is a highly effective therapy for multiple sclerosis (MS) but is linked to a high incidence of PML. The current metrics used to stratify MS patients at risk for PML are incomplete, leading some patients to prematurely discontinue an effective treatment and others to develop PML despite perceived low risk.

Objective

We sought to develop a combination of cell-based assays using peripheral blood which can be used to provide a more comprehensive assessment of immune system function and complement existing PML risk metrics.

Methods

Our assays measure general and JCV specific responses in CD4⁺ and CD8⁺ T cells fo

SUBMITTER: Wu Q 

PROVIDER: S-EPMC12360262 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature